Roseola Infantum (exanthum subitum, sixth disease)
Roseola Infantum (exanthum subitum, sixth disease) ICD-9 058.10
Are You Confident of the Diagnosis?
What you should be alert for in the history
Roseola infamtum is a common infectious disease of infancy characterized by a rash proceeded for 3-5 days by high fever (40-40.5°C; 104-105°F) in an otherwise healthy appearing infant.
Characteristic findings on physical examination
These include rose pink macules and papules on the trunk, neck, extremities, and less commonly on the face. Upper respiratory findings such as injection of the tympanic membranes, in addition to cervical or occipital lymphadenopathy may be appreciated. Red papules on the soft palate may be seen (Nagayama’s spots), as well as uvulo-palatoglossal junction ulcers. Bulging fontanelles, seizures, encephalopathy, or aseptic meningitis may alert the practitioner to neurological involvement
Expected results of diagnostic studies
Laboratory investigations for diagnosing human herpesvirus (HHV) include serologies, antigen detection, PCR, and immunofluorescence.
Differential diagnoses include other viral exanthems such as adenovirus, enterovirus, parvovirus B19, rubella, and parainfluenza.
Who is at Risk for Developing this Disease?
Infants and toddlers between 6 months and 3 years of age are the highest risk group with the peak age being 6-7 months. It is more common in the spring.
What is the Cause of the Disease?
HHV-6 and HHV-7. HHV-6 and HHV-7 is acquired via respiratory droplet. The virus replicates in T cells, although widespread infection is possible. Viremia occurs 2 days prior to the onset of fever, and is self-limiting. Latency is established and most commonly occurs in the salivary glands and peripheral blood mononuclear cells.
Systemic Implications and Complications
Patients with HIV or immunosuppressed patients may experience reactivation of the virus. The non-specific features of fever, malaise, and rash may mimic acute graft-versus-host disease. Bone marrow failure, neurological involvement, or pneumonitis may ensue. Since HHV-6 has several genes which transactivate long terminal repeat (LTR) of HIV, it is proposed that HHV-6 may have a role as the cofactor for AIDS.
In most cases the disease is mild and self-limiting, and treatment is supportive using antipyretics, such as acetaminophen during the febrile stage. In more severe cases, ganciclovir or foscarnet have activity against HHV-6 and HHV-7. The virus is less responsive to acyclovir.
Optimal Therapeutic Approach for this Disease
Use anti-virals as above in severe disease, and control fever with anti-pyretics as needed.
The otherwise healthy infant can be managed as an outpatient. At the onset of the rash, the fever should improve, with the rash resolving in 5-10 days.
In a patient with neurological symptoms, inpatient monitoring is necessary, and initiation of anti-virals should be strongly considered.
Unusual Clinical Scenarios to Consider in Patient Management
Intractable seizures following roseola have been reported.
HHV-6 has been implicated as an etiologic agent in drug hypersensitivity syndomes, with ganciclovir being used therapeutically
What is the Evidence?
Torigoe, S, Kumamoto, T, Koide, W, Taya, K, Yamanishi, K. "Clinical manifestations associated with human herpesvirus 7 infection". Arch Dis Child. vol. 72. 1995 June. pp. 518-519.(Documents association of herpes virus with clinical manifestations of roseola.)
Dyer, JA. "Childhood Viral Exanthems". Pediatr Ann. vol. 36. 2007 Jan. pp. 21-9.(Provides clincal overview of childhood exanthems including roseola.)
Copyright © 2017, 2012 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?
- Olaratumab May Be Safe and Effective in Patients With Advanced Soft Tissue Sarcoma
- Next-Generation Sequencing May Benefit Some Patients With Sarcoma